유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

diurnal europe b.v. - hýdrókortisón - adrenal hyperplasia, congenital - barksterar til almennrar notkunar - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, flútikasón nef - astma - lyf til veikindi öndunarvegi sjúkdómum, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminósýra efnaskipti, innfæddir villur - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

biomarin international limited - valoctocogene roxaparvovec - antihemorrhagics - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - lyf til veikindi öndunarvegi sjúkdómum, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

agepha pharma s.r.o. - prednisolone pivalate - augnsmyrsli - 5 mg/g

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

abcur ab* - metolazonum inn - tafla - 5 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

alcon nordic a/s - proxymetacainum hýdróklóríð - augndropar, lausn - 5 mg/ml

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - calcii carbonas; calcii lacto-gluconas - freyðitafla - 500 mg